目的 探讨心型脂肪酸结合蛋白(H-FABP)对非ST段抬高急性冠脉综合征(non-ST-elevation acute coronary syndromes, NSTE ACS)的诊断意义。方法 选择115例NSTE ACS患者和69例非心脏性胸痛患者(对照组), 应用酶联免疫法测定H-FABP与心肌肌钙蛋白Ⅰ(cTnI)水平, 比较其在非ST段抬高急性心肌梗死(NSTE AMI), 不稳定性心绞痛(UAP)及非心脏性胸痛患者3组人群中的差异。结果 NSTE ACS患者和对照组血清H-FABP水平分别为(459±312)pg/ml和(237±169)pg/ml, 差异有统计学意义(P＜0.05)。NSTE ACS组中, 61例UAP患者H-FABP水平为(340±285)pg/ml, 54例NSTE AMI患者为(592±289)pg/ml, 差异有统计学意义(P＜0.05)。对于胸痛发作后6 h内诊断NSTE AMI, H-FABP的ROC曲线下面积0.863, 敏感性97.1%, 特异性47.6%;cTnI的ROC曲线下面积为0.799, 敏感性为61.2%, 特异性93.9%。结论 H-FABP是一个具有较高敏感性的早期NSTE ACS标志物, 检测H-FABP有助于NSTE ACS诊断。
Abstract
Objective To study the diagnostic value of serum heart-type fatty-acid binding protein(H-FABP)for non-ST-elevation acute coronary syndromes(NSTE ACS). Methods H-FABP and cTnI were measured and compared in 115 NSTE ACS patients and 69 non-cardiac chest pain patients. Results The H-FABP levels were (459±312) pg/ml, (237±169) pg/ml in NSTE ACS group and non-cardiac chest pain group respectively, and there was a significant difference between the two groups(P＜0.05).In NSTE ACS group, the H-FABP level of UAP group was (340±285) pg/ml which was lower than NSTE AMI group (592±289) pg/ml, and there was a significant difference between the two groups(P＜0.05). For the diagnosed NSTE AMI, the area under the ROC curve of H-FABP was 0.863, the sensitivity was 97.1%, specificity was 47.6%; while for the cTnI were 0.799, 61.2%, 93.9%.Conclusions H-FABP is a highly sensitivie marker of the early NSTE ACS and H-FABP detection is conducive to diagnosis of NSTE ACS.
关键词
非ST段抬高急性冠脉综合征 /
心型脂肪酸结合蛋白
Key words
non-ST-elevation acute coronary syndrome /
heart-type fatty-acid binding protein
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Reibis R, Voller H, Gitt A et al. Management of patients with ST-segment elevation or non-ST-segment elevation acute coronary syndromes in cardiac rehabilitation centers [J]. Clin Cardiol, 2014, 37(4): 213-221.
[2] Meier P, Lansky A J, Baumbach A. Almanac 2013: acute coronary syndromes [J]. Acta Cardiol, 2014, 69(1): 100-108.
[3] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南[J]. 中华心血管病杂志, 2007, 35(4): 295-304.
[4] National Committee for Clinical Laboratory Standards. method comparison and bias estimation using patient samples EP09-A2 [J]. Clin Laborat Stand Instit, 2002, 22(19):1-52.
[5] 府伟灵, 徐克前. 临床生物化学检验[M]. 5版. 北京: 人民卫生出版社, 2011: 218-220.
[6] Wenger N K. 2011 ACCF/AHA focused update of the guidelines for the management of patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 Guideline): highlights for the clinician [J]. Clin Cardiol, 2012, 35(1): 3-8.
[7] 贺 延, 田东华, 吕俊刚, 等. 脑钠素与非ST段抬高型心肌梗死冠状动脉病变程度的关系[J]. 武警医学, 2009, 20(9): 808-809.
[8] 杨 丽, 彭 辉, 刘 琴, 等. 探讨血清心肌标志物与急性冠脉综合征患者危险分层的相关性[J]. 标记免疫分析与临床, 2014, 21(2): 127-131.
[9] 康可人, 吴培钿, 李悦琳, 等. 抗心型脂肪酸结合蛋白单克隆抗体制备、鉴定和在侧向免疫层析方法中的应用[J]. 中国生物工程杂志, 2013, 38(1):72-78.
基金
湖南省科技厅科技计划基金(2013FJ3136)
PDF(593 KB)
